This trial is conducted in Europe. The aim of this trial is to compare insulin aspart produced by current process and the NN2000 process.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
28
Single dose of each formulation administrated subcutaneously (s.c., under the skin) at two separate dosing visits
Novo Nordisk Investigational Site
Manchester, United Kingdom
Area under the Curve (AUC) (insulin aspart)
Cmax (maximum plasma concentration)
Terminal half life (t½)
Incident of hypoglycaemic episodes
Adverse events
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.